David A Lomas Selected Research

Lung Diseases (Lung Disease)

5/2021	The Importance of N186 in the Alpha-1-Antitrypsin Shutter Region Is Revealed by the Novel Bologna Deficiency Variant.
1/2019	Characterisation of a type II functionally-deficient variant of alpha-1-antitrypsin discovered in the general population.
8/2018	New Therapeutic Targets for Alpha-1 Antitrypsin Deficiency.
1/2016	Update on alpha-1 antitrypsin deficiency: New therapies.
1/2016	α1-Antitrypsin deficiency.
2/2012	Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Lomas Research Topics

Disease

97	Chronic Obstructive Pulmonary Disease (COPD) 02/2023 - 07/2007
45	Emphysema 03/2024 - 06/2002
30	Dementia (Dementias) 11/2019 - 05/2002
20	Fibrosis (Cirrhosis) 01/2022 - 03/2002
18	Brain Diseases (Brain Disorder) 11/2019 - 10/2002
17	Inflammation (Inflammations) 01/2023 - 05/2006
16	Liver Diseases (Liver Disease) 03/2024 - 03/2002
15	Alzheimer Disease (Alzheimer's Disease) 12/2013 - 03/2002
9	Thrombosis (Thrombus) 05/2009 - 04/2003
7	Pneumonia (Pneumonitis) 07/2021 - 12/2016
6	Lung Diseases (Lung Disease) 05/2021 - 02/2012
6	Familial encephalopathy with neuroserpin inclusion bodies 09/2016 - 05/2002
6	Hepatocellular Carcinoma (Hepatoma) 05/2013 - 07/2003
5	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 02/2005
5	Neonatal hemochromatosis 05/2013 - 03/2002
4	Cardiovascular Diseases (Cardiovascular Disease) 06/2020 - 07/2013
4	Disease Progression 01/2017 - 10/2012
3	Cachexia 05/2020 - 08/2012
3	Atherosclerosis 01/2018 - 01/2015
3	Amyloidosis 01/2012 - 03/2002
2	Weight Loss (Weight Reduction) 12/2021 - 05/2020
2	Epilepsy (Aura) 09/2016 - 08/2004
2	Vasculitis (Vasculitides) 09/2013 - 03/2013
2	Infections 09/2013 - 05/2006
2	Pancreatic Neoplasms (Pancreatic Cancer) 08/2013 - 10/2012
2	Obstructive Lung Diseases (Obstructive Lung Disease) 03/2012 - 11/2010
2	Ischemic Stroke 05/2011 - 03/2011
2	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2010 - 10/2007
2	Angioedema 01/2009 - 04/2003
2	Necrosis 02/2008 - 09/2006
2	Hepatitis 11/2004 - 08/2003
1	Cystic Fibrosis (Mucoviscidosis) 09/2022
1	Cholelithiasis 01/2022
1	Liver Neoplasms (Liver Cancer) 01/2022
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Fatigue 05/2020
1	Anorexia 05/2020
1	Anemia 05/2020

Drug/Important Bio-Agent (IBA)

45	Biomarkers (Surrogate Marker)IBA 02/2023 - 09/2010
37	PolymersIBA 03/2024 - 05/2002
33	NeuroserpinIBA 11/2019 - 05/2002
29	Proteins (Proteins, Gene)FDA Link 03/2024 - 03/2002
15	SerpinsIBA 11/2019 - 10/2002
14	GSK573719IBA 06/2021 - 01/2017
14	fluticasone furoate FDA Link 06/2021 - 01/2017
14	vilanterolIBA 06/2021 - 01/2017
12	Fibrinogen (Factor I)FDA Link 07/2021 - 11/2011
11	Peptide Hydrolases (Proteases)FDA Link 03/2024 - 05/2002
11	GoldIBA 12/2018 - 09/2010
9	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 12/2020 - 09/2004
9	Peptides (Polypeptides)IBA 01/2014 - 03/2003
8	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2021 - 07/2012
7	AntithrombinsIBA 05/2009 - 04/2003
5	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 08/2014 - 03/2011
5	Amyloid (Amyloid Fibrils)IBA 12/2013 - 10/2007
4	Protease Inhibitors (Protease Inhibitor)IBA 01/2023 - 11/2010
4	Serine Proteases (Serine Protease)IBA 01/2023 - 03/2010
4	nasIBA 02/2012 - 03/2009
3	EnzymesIBA 01/2022 - 03/2013
3	C-Reactive ProteinIBA 07/2021 - 12/2012
3	CalciumIBA 11/2019 - 08/2014
3	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2019 - 03/2013
3	Bronchodilator Agents (Bronchodilators)IBA 08/2012 - 09/2011
3	Amyloid beta-PeptidesIBA 04/2010 - 04/2009
3	amyloid beta-protein (1-42)IBA 04/2009 - 03/2003
3	alpha 1-Antichymotrypsin (alpha 1 Antichymotrypsin)IBA 01/2009 - 03/2003
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 05/2006
2	IronIBA 05/2020 - 02/2011
2	Muscarinic AntagonistsIBA 05/2018 - 04/2018
2	p38 Mitogen-Activated Protein KinasesIBA 01/2018 - 03/2012
2	6- (5- ((cyclopropylamino)carbonyl)- 3- fluoro- 2- methylphenyl)- N- (2,2- dimethylprpyl)- 3- pyridinecarboxamideIBA 01/2018 - 03/2012
2	Budesonide (Pulmicort)FDA LinkGeneric 01/2018 - 01/2017
2	Monoclonal AntibodiesIBA 01/2018 - 09/2010
2	Formoterol Fumarate (Oxis)FDA Link 01/2018 - 01/2017
2	Fluticasone (Cutivate)FDA LinkGeneric 01/2018 - 03/2012
2	AsparagineIBA 12/2015 - 10/2012
2	Receptor for Advanced Glycation End ProductsIBA 10/2015 - 10/2013
2	P-2 (P 2)IBA 01/2015 - 12/2010
2	Interleukin-8 (Interleukin 8)IBA 08/2014 - 09/2013
2	Messenger RNA (mRNA)IBA 01/2014 - 10/2009
2	Interleukin-6 (Interleukin 6)IBA 09/2013 - 11/2011
2	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 08/2013 - 03/2010
2	Blood Proteins (Serum Proteins)IBA 07/2013 - 01/2009
2	SmokeIBA 04/2013 - 12/2009
2	Amino Acids FDA Link 03/2013 - 10/2012
2	Glutamine (L-Glutamine)FDA Link 10/2012 - 08/2012
2	Tissue Plasminogen Activator (Alteplase)FDA Link 03/2011 - 08/2004
2	Heparin Cofactor IIIBA 01/2009 - 09/2006
2	PrionsIBA 09/2004 - 10/2002
1	Genetic Markers (Genetic Marker)IBA 02/2023
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 09/2022
1	Insulin (Novolin)FDA Link 01/2021
1	CytokinesIBA 01/2021
1	omega-Chloroacetophenone (Mace)IBA 06/2020
1	Heme (Haem)IBA 05/2020
1	Hemoglobins (Hemoglobin)IBA 05/2020
1	Small Interfering RNA (siRNA)IBA 08/2018
1	GlucocorticoidsIBA 05/2018

Therapy/Procedure

34	Therapeutics 03/2022 - 03/2002
14	Nebulizers and Vaporizers (Inhaler) 03/2022 - 01/2017